{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:30:39Z","timestamp":1791822639182,"version":"4.3.4"},"reference-count":27,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Background: Immunoadsorption and intravenous immunoglobulin (IVIG) administration may have beneficial effects in patients with dilated cardiomyopathy with end-stage heart failure. We investigated the effect of immunoadsorption with subsequent IVIG administration on cardiac function and symptoms in patients on optimal medical treatment (OMT) for heart failure (HF) with recent-onset cardiomyopathy during long-term follow-up. Methods: Thirty-five patients with recent-onset of HF symptoms received intensive guideline-recommended medical HF therapy for 5.2 months. Subsequently, all patients received a single cycle of immunoadsorption for five days followed by IVIG administration. During the 29-month follow-up period, New York Heart Association (NYHA) functional class, left ventricular ejection fraction (LVEF) and N-terminal pro brain natriuretic peptide (NT-proBNP) were evaluated. Changes in quality of life (QoL) were assessed using the Minnesota Living with HF Questionnaire. Results: Three months after immunoadsorption, NYHA functional class improved from 2.0 to 1.5 (p &lt; 0.005) and LVEF significantly increased from 27.0% to 39.0% (p &lt; 0.0001). Long-term follow-up of 29 months showed stable NYHA functional class and a further moderate increase in LVEF from 39.0% to 42.0% (p &lt; 0.0001) accompanied by a significant improvement in NT-proBNP and QoL scores. Conclusion: Immunoadsorption followed by IVIG administration further enhances LVEF, HF symptoms, QoL and biomarkers in patients with recent-onset HF on OMT.<\/jats:p>","DOI":"10.3390\/biom8040133","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T04:26:39Z","timestamp":1541391999000},"page":"133","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure\u2014A Single Center Experience"],"prefix":"10.3390","volume":"8","author":[{"given":"Karolina","family":"Weinmann","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Rottbauer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Walcher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-0508","authenticated-orcid":false,"given":"Mirjam","family":"Ke\u00dfler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00395-016-0569-y","article-title":"Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution","volume":"111","author":"Ameling","year":"2016","journal-title":"Basic Res. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08916930109007385","article-title":"Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy","volume":"34","author":"Caforio","year":"2001","journal-title":"Autoimmunity"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clim.2009.04.008","article-title":"Cardiac troponins and autoimmunity: Their role in the pathogenesis of myocarditis and of heart failure","volume":"134","author":"Kaya","year":"2010","journal-title":"Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.19.1.80-94.2006","article-title":"Molecular mimicry, bystander activation, or viral persistence: Infections and autoimmune disease","volume":"19","author":"Fujinami","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.molimm.2003.11.023","article-title":"T cell mimicry in inflammatory heart disease","volume":"40","author":"Cunningham","year":"2004","journal-title":"Mol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM199508033330501","article-title":"A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators","volume":"333","author":"Mason","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0735-1097(85)80312-0","article-title":"A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis","volume":"6","author":"Reap","year":"1985","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11560-013-0843-z","article-title":"Plasmapherese und Immunadsorption","volume":"9","author":"Renders","year":"2014","journal-title":"Nephrologe"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0002-8703(92)90986-6","article-title":"Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group","volume":"124","author":"Rector","year":"1992","journal-title":"Am. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/0002-9149(93)90582-W","article-title":"Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo","volume":"71","author":"Rector","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jjcc.2016.07.014","article-title":"Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry","volume":"69","author":"Ohlow","year":"2017","journal-title":"J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"(1997). The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur. Heart J., 18, 736\u2013753.","DOI":"10.1093\/oxfordjournals.eurheartj.a015339"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0735-1097(00)00568-4","article-title":"Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study","volume":"35","author":"Felix","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0735-1097(99)00485-4","article-title":"Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis","volume":"35","author":"Lauer","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.CIR.101.4.385","article-title":"Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy","volume":"101","author":"Muller","year":"2000","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrcardio.2016.134","article-title":"2016 ESC and ACC\/AHA\/HFSA heart failure guideline update\u2014What is new and why is it important?","volume":"13","author":"Jessup","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"712.e1","DOI":"10.1016\/j.ahj.2006.06.027","article-title":"Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study","volume":"152","author":"Staudt","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1161\/01.CIR.0000036746.49449.64","article-title":"Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy","volume":"106","author":"Staudt","year":"2002","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/clpt.2009.246","article-title":"Fcgamma-receptor IIa polymorphism and the role of immunoadsorption in cardiac dysfunction in patients with dilated cardiomyopathy","volume":"87","author":"Staudt","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/0735-1097(94)00543-Y","article-title":"Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade","volume":"25","author":"Hall","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJM200501063520123","article-title":"Autoantibodies against cardiac troponins","volume":"352","author":"Eriksson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/eurheartj\/ehs330","article-title":"Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy","volume":"34","author":"Ameling","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/eurjhf\/hfs123","article-title":"Long-term benefits of immunoadsorption in beta(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy","volume":"14","author":"Dandel","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2362.2010.02314.x","article-title":"Immunoadsorption in dilated cardiomyopathy: Long-term reduction of cardiodepressant antibodies","volume":"40","author":"Trimpert","year":"2010","journal-title":"Eur. J. Clin. Investig."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/8\/4\/133\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:27:40Z","timestamp":1760196460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/8\/4\/133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["biom8040133"],"URL":"https:\/\/doi.org\/10.3390\/biom8040133","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]}}}